A new therapeutic paradigm: radioiodine combined with lenvatinib for radioiodine-avid metastatic well-differentiated thyroid cancer

Nuclear Medicine Communications, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Purpose Management of metastatic well-differentiated thyroid cancer (WDTC) remains challenging, with significant morbidity and mortality. Multidisciplinary treatment, along high-dose radioiodine therapy (HDRI), a mainstay. Morbidity mortality benefits are noted, seldom complete response. The foremost concerns HDRI side effects, refractoriness, macronodular lung, bone metastasis. Lenvatinib is standard care in radioiodine-refractory disease. However, it unexplored radioiodine-avid WDTC. This study investigates the effect lenvatinib improving disease control progression Material methods Fifteen patients WDTC were enrolled or without prior HDRI. burden was evaluated imaging [whole-body scan (WBRI), PET–computed tomography (CT), CT] serum thyroglobulin (Tg) measurement. After excluding contraindication, given for 3 months, thyroxine suppression. Adverse effects monitored. Thyroxin withdrawn, patient underwent WBRI followed by Treatment response based on [response evaluation criteria solid tumors (RECIST), PET (PERCIST), WBRI] tumor marker parameters. Results mean age 52.0 ± 14.2 years. Lung metastases noted (12, 80%) 10 (66%) patients. Nine (60%) already had (242.5 140.3 mCi). well-tolerated, two-thirds having grade I toxicities. During follow-up (14.79 5.93 months), one died pneumonia unrelated to Tg level fell from 45 800.8 69 283.9 [median: 7094.0, interquartile range (IQR): 988.3–114 397.0] 672.5 18 490.5 (median: 1796.0, IQR: 171.0–17 090.0) ng/ml. fall not associated ( P > 0.05) age, sex, histopathology, previous Partial stable four patients, respectively, (PERSIST RECIST criteria) levels. One imaging. Conclusion HDRI, combination lenvatinib, demonstrated potential treatment well-tolerated. There an unprecedented partial single cycle therapy. While small sample size limited study, preliminary data suggest that synergistic may improve control. Further investigation larger cohort warranted confirm findings explore predictors.

Язык: Английский

---

Thyroid cancer: Clinical landscape

Elsevier eBooks, Год журнала: 2025, Номер unknown, С. 163 - 193

Опубликована: Янв. 1, 2025

Язык: Английский

---

Identification of thyroid cancer biomarkers using WGCNA and machine learning

European journal of medical research, Год журнала: 2025, Номер 30(1)

Опубликована: Апрель 5, 2025

Язык: Английский

---

Understanding the Disease Experiences of Thyroid Cancer Survivors with Distant Metastases: A Qualitative Descriptive Study

European Journal of Oncology Nursing, Год журнала: 2025, Номер unknown, С. 102893 - 102893

Опубликована: Апрель 1, 2025

Язык: Английский

---

Which factors affect treatment success/prognosis in thyroid cancers with pulmonary metastases and what is/how should be the effective cumulative cure/dose as a current approach; A retrospective study

Research Square (Research Square), Год журнала: 2025, Номер unknown

Опубликована: Апрель 17, 2025

Objective Our primary objective in this study was to analyse clinical-prognostic factors, evaluate their effects on response RAIT and survival pulmonary metastatic differantiated thyroid cancer. Another aim the treatment cycles/doses achive effective at end of follow-up. Methods 68 patients with differentiated cancer who met all inclusion criteria were included. Clinical-pathological features imaging findings collected analysed retrospectively. Results Advanced age (p 0.037, OR 1.045), > 2 cm tumor (p: 0.009, 8), macronodular metastases 0.024, 3.7) non-RAI-avidity 0.045, 4.5) independent factors associated non-response RAIT. When cumulative responses first 3 cycles compared, no significant change observed until 3rd cycle (up a dose 21.27 GBq). That is, excluding achieved excellent ≤ cycles, it would be appropriate administer least (21.27 GBq) achieve indeterminate resonse, which constitutes another pillar good prognostic group. Conclusion Collectively, consider that decreases advanced presence metastases. In addition this, concluded may determination treatment-resistant cases, other words, cases biochemical-structural incomplete can obtained during

Язык: Английский

---

Thyroid cancer and cardiovascular diseases: a Mendelian randomization study

Frontiers in Cardiovascular Medicine, Год журнала: 2024, Номер 11

Опубликована: Апрель 25, 2024

Background Multiple observational studies have shown associations between thyroid cancer (TC) and cardiovascular diseases (CVDs). However, the results were inconsistent, potential causal genetic relationship remains unclear. Methods The instruments of TC CVDs derived from data obtained through genome-wide association (GWAS). We performed two-sample Mendelian randomization(MR) methods to investigate causality on CVDs. Summary-level statistics for CVDs, including heart failure (HF), atrial fibrillation (AF), coronary artery disease (CAD), myocardial infarction (MI), ischemic stroke (IS) venous thromboembolism (VTE). primary method employed in this MR analysis was Inverse Variance Weighted (IVW) approach, four additional algorithms used: MR-Egger, weighted median, simple mode, mode. Additionally, we assessed reliability pleiotropy, heterogeneity leave-one-out sensitivity analysis. Results In analysis, only detected genetically predicted HF (IVW method, odds ratio (OR) = 1.00134, 95% confidence interval (CI): 1.00023–1.00244, p 0.017). There no with CAD, MI, AF, IS, VTE. Conclusion Our confirmed HF. It is crucial closely monitor incidence patients give comprehensive clinical intervention based conventional treatment.

Язык: Английский

---

Novel Platinum(IV) complexes intervene oxaliplatin resistance in colon cancer via inducing ferroptosis and apoptosis

European Journal of Medicinal Chemistry, Год журнала: 2023, Номер 263, С. 115968 - 115968

Опубликована: Ноя. 19, 2023

Язык: Английский

---

Choice of management strategy for papillary thyroid microcarcinoma: active surveillance or immediate surgery?

Journal of Cancer, Год журнала: 2024, Номер 15(4), С. 1009 - 1020

Опубликована: Янв. 1, 2024

Overdiagnosis of papillary thyroid microcarcinoma (PTMC) is prevalent, and effective management PTMC an important matter.The high incidence low mortality rate carcinoma (PTC) justify the preference for active surveillance (AS) over immediate surgery (IS), particularly in cases low-risk PTMC.Japan began AS 1990s as alternative surgical option it has shown promising results.The safety efficacy have been verified.However, may not be suitable all cases.How to find balance between decision-making IS requires careful consideration.Therefore, we collected analyzed relevant evidence on clinical strategies PTC discussed from perspectives health, economic, psychological aspects, help clinicians choosing a more appropriate strategy PTC.

Язык: Английский

---

TIPARP as a prognostic biomarker and potential immunotherapeutic target in male papillary thyroid carcinoma

Cancer Cell International, Год журнала: 2024, Номер 24(1)

Опубликована: Янв. 17, 2024

Abstract Background Male patients with papillary thyroid carcinoma (PTC) tend to have poorer prognosis compared females, partially attributable a higher rate of lymph node metastasis (LNM). Developing precise predictive model for LNM occurrence in male PTC is imperative. While preliminary models exist, there room improve accuracy. Further research needed create optimized prognostic specific prediction cases. Methods We conducted comprehensive search publicly available microarray datasets identify candidate genes continuously upregulated or downregulated during progression only. Univariate Cox analysis and lasso regression were utilized construct an 11-gene signature LNM. TIPARP emerged as key gene, which we validated at the protein level using immunohistochemical staining. A nomogram incorporating clinical factors was developed based on TCGA cohort. Results The demonstrated good discriminative performance training validation datasets. High expression associated advanced stage, high T presence integrating variables reliably stratified into low recurrence risk groups. Conclusions identified robust predicting patients. propose potential contributor inferior outcomes males, warranting further exploration biomarker immunotherapeutic target. Our study provides insights molecular basis gender disparities PTC.

Язык: Английский

---

How to Manage Advanced Differentiated Thyroid Cancer: Step-by-Step Analysis from Two Italian Tertiary Referral Centers

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(3), С. 708 - 708

Опубликована: Янв. 25, 2024

Differentiated thyroid carcinoma (DTC) has an excellent prognosis; however, advanced disease is associated with a worse prognosis and relatively common. Surgery followed by RAI treatment remains the mainstream for large majority of patients high- intermediate-risk DTC, but its benefits should be carefully weighed against potential harm. The aim this paper to critically review experience in treating DTC at two tertiary referral centers Italy. Retrospective analysis 300 who underwent surgery ADTC over 30 years. complication rate was 50.33%. A total 135 (45%) remained regular follow-up, 118 (87.4%) were alive, while 17 (12.6%) deceased. mean overall survival 12 years 84.8% 238 months. Eleven (8.1%) experienced relapse after median 13 adequately treated can achieve prolonged even case metastasis or relapse. Patients referred high-volume availability extended multidisciplinary team receive tailored treatment.

Язык: Английский

---